Date of Original Version
The promise of pharmacogenomics depends on advancing predictive medicine. To address this need in the area of immunology, we developed the individualized T cell epitope measure (iTEM) tool to estimate an individual's T cell response to a protein antigen based on HLA binding predictions. In this study, we validated prospective iTEM predictions using data from in vitro and in vivo studies. We used a mathematical formula that converts DRB1 allele binding predictions generated by EpiMatrix, an epitope-mapping tool, into an allele-specific scoring system. We then demonstrated that iTEM can be used to define an HLA binding threshold above which immune response is likely and below which immune response is likely to be absent. iTEM's predictive power was strongest when the immune response is focused, such as in subunit vaccination and administration of protein therapeutics. iTEM may be a useful tool for clinical trial design and preclinical evaluation of vaccines and protein therapeutics.
Tobias Cohen, Leonard Moise, Matthew Ardito, William Martin, and Anne S. De Groot, “A Method for Individualizing the Prediction of Immunogenicity of Protein Vaccines and Biologic Therapeutics: Individualized T Cell Epitope Measure (iTEM),” Journal of Biomedicine and Biotechnology, vol. 2010, Article ID 961752, 7 pages, 2010. https://doi.org/10.1155/2010/961752.
Available at: http://dx.doi.org/10.1155/2010/961752
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.